Komori
Astena Holdings (8095) · PolicyAdvanced

Enhancing Corporate Governance, Compliance and Transparency

First written in FY2016. 2 of 5 entries say "Restated". Latest entry: FY2024.

5entries
9years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2016 – FY2017AdvancedFY2018RestatedFY20202017: 120172018: 120182019: 120192020: 020202021: 120212022: 020222023: 020232024: 020242025: 1
Same theme, other companies
Integrated Strengthening of Internal Controls, Corporate Governance and ComplianceA theme 351 companies write about · 2 as a headwind · 350 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 200 companies compared. The sentences above are computed from all 200.Comparing 200 of the theme's 352 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2024AdvancedAnnual report

    「We have established a Nomination and Compensation Advisory Committee to consider important matters concerning the nomination and compensation of directors. It serves as an advance advisory body to the Board of Directors. The committee is chaired by an outside director and consists solely of outside directors and Audit & Supervisory Board members, ensuring independence and objectivity.」

    A structure was specified in which the Nomination and Compensation Advisory Committee is chaired by an outside director and consists solely of outside directors and Audit & Supervisory Board members. The Board of Directors met 17 times during the fiscal year.
  2. FY2020RestatedAnnual report

    「We recognize that improving the compliance framework and the transparency of corporate management are important management issues, and are strengthening corporate governance to ensure that these objectives are fully implemented.」

    Compliance, transparency, and enhancement of corporate value were reaffirmed as important governance issues, and the framework, including three advisory committees chaired by outside directors, remains in place.
  3. FY2018AdvancedAnnual report

    「The three advisory committees, the Nomination Advisory Committee, Compensation Advisory Committee, and Corporate Governance Advisory Committee, serve as bodies that provide advance advice to the Board of Directors. Each is chaired by an outside director and consists of certain directors and outside directors, as well as certain Audit & Supervisory Board members, both internal and external.」

    The establishment and composition of three advisory committees chaired by outside directors were described as a specific corporate governance practice.
  4. FY2017RestatedAnnual report

    「We recognize that improving the compliance framework and the transparency of corporate management are important management issues, and are strengthening corporate governance to ensure that these objectives are fully implemented.」

    Compliance, transparency, and enhancement of corporate value were reaffirmed as important corporate governance issues.
  5. FY2016First statedAnnual report

    「We recognize that improving the compliance framework and the transparency of corporate management are important management issues, and are strengthening corporate governance to ensure that these objectives are fully implemented.」

    Enhancement of corporate value, compliance, and transparency were organized as the basic policies for corporate governance, and the frameworks of the Board of Directors, Audit & Supervisory Board, Internal Audit Office, and other bodies were described in detail.
Moved together

"Overseas Expansion and Product Development in Chemicals, New Equipment and Optimal-Site Production" moved the same way as this thread, in the same document, in 2 of its 5 moves.

222222★123456
  1. ★This thread
  2. 1Overseas Expansion and Product Development in Chemicals, New Equipment and Optimal-Site Production2×
  3. 2Revenue and profit growth in the Pharmaceutical and Franchise Businesses2×
  4. 3Sharp Decline in Chemicals Business Revenue and Widening Operating Loss2×
  5. 4Expanding Sales of Generic Pharmaceutical Ingredients and New Materials Through Customer Proposals2×
  6. 5HBC business: slight sales growth, lower operating income2×
  7. 6Earnings Pressure on the Pharmaceutical Business from Drug Price Revisions2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Astena Holdings yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Enhancing Corporate Governance, Compliance and Transparency | Astena Holdings Co.,Ltd. (8095) | Komori